AG真人官方

Form 144 filing for BioNTech SE (BNTX) shows a proposed sale of 1,774,837 American Depositary Shares representing ordinary shares, with an aggregate market value of $200,024,129.90. The sale is reported through Berenberg Capital Markets LLC on 08/15/2025 and the shares are listed on the Nasdaq Global Select. The filing discloses that the seller acquired the underlying ordinary shares via stock option exercises on 08/09/2024 (918,651 shares) and 11/21/2022 (856,186 shares). The filing reports no sales in the prior three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.

Form 144 filed for BioNTech SE (BNTX) reporting a proposed sale of 185,001 American Depositary Shares (ADS) representing ordinary shares. The broker listed is Berenberg Capital Markets LLC with an approximate sale date of 08/15/2025 on Nasdaq Global Select. The aggregate market value of the proposed sale is reported as $20,849,612.70 and the number of shares outstanding is listed as 240,398,724. The securities were acquired on 11/21/2022 through a stock option exercise from BioNTech SE. The filer reports no securities sold in the past three months and includes the standard certification that the seller is not aware of undisclosed material adverse information.

BioNTech announced settlement arrangements resolving U.S. patent litigation with CureVac and related arrangements with GSK and Pfizer. The parties agreed to dismiss U.S. patent claims and BioNTech received a non-exclusive U.S. license (with sublicensing rights) to make, use, sell and import mRNA vaccines for COVID-19 and influenza developed with Pfizer. The deal creates royalty and cash obligations: BioNTech will pay $370 million to GSK and $370 million to CureVac under specified triggers, plus a 1% royalty on U.S. sales of licensed products to each of GSK and CureVac effective January 1, 2025.

Subject to closing of BioNTech鈥檚 planned acquisition of CureVac, the company will obtain worldwide non-exclusive licenses, the parties must dismiss non-U.S. claims, BioNTech will pay an additional $130 million to GSK upon certain later conditions, and Pfizer agreed to reimburse BioNTech $80 million plus half of claimed GSK royalties from January 1, 2025 for COVID-19 mRNA products. The company disclaims any admission of liability and highlights transactional and regulatory risks.

Filing: On August 4, 2025, BioNTech SE filed a Form 6-K reporting a development update and its financial results for the three and six months ended June 30, 2025.

Exhibit: The filing states that the interim condensed consolidated financial statements and the operating and financial review and prospects for the three and six months ended June 30, 2025 are attached as Exhibit 99.1 and are deemed filed under Section 18 of the Exchange Act.

Signatures: The report is signed by Ram贸n Zapata-Gomez, Chief Financial Officer, and Dr. Sierk Poetting, Chief Operating Officer, dated August 4, 2025. The Form 6-K body contains no financial line-item figures; readers are referred to Exhibit 99.1 for detailed results.